Abstract: A compound represented by the following formula (1): wherein in the formula (1), rings X1 to X4 independently a substituted or unsubstituted benzene ring, or a substituted or unsubstituted 6-membered aromatic heterocyclic ring having one or two nitrogen atoms, and at least two of the rings X1 to X4 are independently fused with one or more selected from the group consisting of a substituted or unsubstituted hydrocarbon ring including 5 to 50 ring carbon atoms, and a substituted or unsubstituted heterocyclic ring including 5 to 50 ring atoms.

Abstract: Provided are compound represented by Formula 1, an organic electric element including a first electrode, a second electrode, and an organic material layer formed between the first electrode and the second electrode, and electronic device thereof, and by including the compound represented by Formula 1 in the organic material layer, the driving voltage of the organic electric element can be lowered, and the luminous efficiency and life time of the organic electric element can be improved.

Abstract: A compound for an organic optoelectronic device, an organic optoelectronic device including the same, and a display device, the compound being represented by Chemical Formula 1:

Abstract: The invention provides agents that target carbonic anhydrase, which can be used as imaging agents or therapeutic agents. The agents can be used to image tumor hypoxia as well as other physiological processes in a subject.

Abstract: A compound having a structure represented by the following formulas (a) and (b): wherein, in the formulas (a) and (b), a ring A, a ring B, a ring C and a ring D are independently a substituted or unsubstituted aromatic hydrocarbon ring having 6 to 50 ring carbon atoms, or a substituted or unsubstituted heterocyclic ring having 5 to 50 ring atoms; two or more of the ring A, the ring B, the ring C and the ring D are a heterocyclic ring; and each of sites *a, *b, *c and *d in the formula (a) and the formula (b) represents a position of an atom, and the atoms located in the sites *a, *b,*c and *d form one substituted or unsubstituted and saturated or unsaturated six-membered ring including four atoms thereof.

Abstract: Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1.

Abstract: A hardmask composition and a method of forming patterns using the hardmask composition, the composition including a polymer including a moiety derived from a compound represented by Chemical Formula 1; and a solvent:

Abstract: A condensed cyclic compound and an organic light-emitting device including the condensed cyclic compound are provided. The condensed cyclic compound is represented by Formula 1. The A3 ring of Formula 1 is a group represented by Formula 2A or a group represented by Formula 2B. The organic light-emitting device includes: a first electrode; a second electrode; and an organic layer between the first electrode and the second electrode and including an emission layer, the organic layer including at least one of the condensed cyclic compound represented by Formula 1.

Abstract: The present specification relates to a hetero-cyclic compound and an organic light emitting device comprising the same.

Abstract: The present invention relates to specific salts of (1S,5R)-(1?,5?,6?)-N-[1,1-dimethyl-2-[(3-methyl-2-pyridyl)oxy]ethyl]-3-azabicyclo[3.1.0]hexane-6-carboxamide, to pharmaceutical compositions comprising said salts, to methods of using said salts to treat physiological disorders, and to intermediates useful in the synthesis of the salts.

Abstract: Provided are a polymer semiconductor including a first structural unit represented by Chemical Formula 1 and a second structural unit represented by Chemical Formula 2, a stretchable polymer thin film including the same, and an electronic device. Definitions of Chemical Formulas 1 and 2 are as described in the detailed description.

Abstract: There is provided a compound of formula (I), wherein L1 to L3?, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.

Abstract: The present specification relates to an organic light emitting device comprising a first electrode, a second electrode, and one or more organic material layers provided between the first electrode and the second electrode, wherein one or more layers of the organic material layers comprise a heterocyclic compound represented by Chemical Formula 1 and a heterocyclic compound represented by Chemical Formula 2 at the same time, and a composition for an organic material layer of an organic light emitting device.

Abstract: A light emitting device having excellent external quantum efficiency contains an anode, a cathode, and two organic layers disposed therebetween. One layer contains a phosphorescent transition metal complex and a low molecular weight compound containing no transition metal, and the second layer contains a crosslinked body of a polymer compound (having an energy level of the lowest triplet excited state of 2.30 eV or more) containing a constitutional unit having a crosslinking group. The low molecular weight compound has formula (T-1) and the absolute value of the difference between the energy levels of the lowest triplet excited state and the lowest singlet excited state is less than 0.25 eV. nT1 represents an integer of 0 to 5, nT2 represents an integer of 1 to 10, ArT1 represents a substituted amino group or a monovalent hetero ring group, LT1 represents an alkylene group, and ArT2 represents a hetero ring group.

Abstract: Provided is a heterocyclic compound of Chemical Formula 1: where L1 is a single bond or a substituted or unsubstituted C6-60 arylene; L2 is a single bond, a substituted or unsubstituted C6-60 arylene, or a substituted or unsubstituted C5-60 heteroarylene, and Ar1 is one of the following Chemical Formulas 2, 3, 4, or 5: and an organic light emitting device including the same.

Abstract: Provided is an ink jet recording ink including: a colorant represented by the following Formula 1, in which an absorption maximum of a dry material of the ink jet recording ink is 700 nm to 1000 nm.

Abstract: The present invention provides heteroaryl functionalized cyanine dyes including a reactive functional moiety, or which are conjugated to a carrier molecule.

Abstract: A novel carbazole compound is provided which can be used as a host material for a light-emitting substance (substance emitting fluorescence or substance emitting phosphorescence). A light-emitting element with high emission efficiency, and a light-emitting device, an electronic device, or a lighting device which has low power consumption are provided. A carbazole compound represented by General Formula (G1) below. (In the formula, Ar1 represents any of hydrogen, a substituted or unsubstituted phenyl group, and a carbazolyl group; R1 to R3 each independently represent any of hydrogen, a substituted or unsubstituted phenyl group, and a substituted or unsubstituted biphenyl group; ? represents any of a substituted or unsubstituted phenylene group and a substituted or unsubstituted biphenylene group; and n is any of 0, 1, and 2.

Abstract: An organic compound represented by Chemical Formula 1, an organic optoelectric device including the organic compound, and a display device are disclosed.

Abstract: The present invention relates to a novel process for the preparation of of the formula (I) (I) wherein R1 and R2 are described herein. The compounds prepared by the present invention are useful in the synthesis and manufacture of compounds for treating diseases or conditions associated with inhibiting actin polymerization.

Abstract: The present invention relates to ethynyl derivatives of formula I wherein R1 is phenyl, which is optionally substituted by 1-2 halogen atoms; selected from fluorine or chlorine; or to a pharmaceutically acceptable acid addition salt in enantiomerically pure form. It has been found that the compounds of general formula I are allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5).

Abstract: Heteroaryl cyanine dyes bearing sulfonic acid substituents are of use in various assays, including single molecule nucleic acid sequencing. Exemplary heteroaryl cyanines dyes include or more reactive functional group, which is of use to covalently conjugate the cyanine dye to a carrier molecule. An exemplary carrier molecule is an analyte molecule or other molecule of interest, for example, a nucleotide oligophosphate.

Abstract: The present invention relates to certain substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases.

Abstract: The present invention relates to ethynyl derivatives of formula I wherein R1 is phenyl, which is optionally substituted by 1-2 halogen atoms; selected from fluorine or chlorine; or to a pharmaceutically acceptable acid addition salt in enantiomerically pure form. It has been found that the compounds of general formula I are allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5).

Abstract: A novel carbazole compound is provided which can be used as a host material for a light-emitting substance (substance emitting fluorescence or substance emitting phosphorescence). A light-emitting element with high emission efficiency, and a light-emitting device, an electronic device, or a lighting device which has low power consumption are provided. A carbazole compound represented by General Formula (G1) below. (In the formula, Ar1 represents any of hydrogen, a substituted or unsubstituted phenyl group, and a carbazolyl group; R1 to R3 each independently represent any of hydrogen, a substituted or unsubstituted phenyl group, and a substituted or unsubstituted biphenyl group; ? represents any of a substituted or unsubstituted phenylene group and a substituted or unsubstituted biphenylene group; and n is any of 0, 1, and 2.

Abstract: Methods and small molecule compounds for stem cell differentiation and treatment of animals with diseases are provided. One example of a class of compounds that may be used is represented by the compound of Formula I and II: or a pharmaceutically acceptable salt or solvate thereof, wherein A, X, Q, R1, R2, R3, R4 are as described herein.

Abstract: A chrysene-based compound and an organic light-emitting device including the same, the chrysene-based compound being represented by Formula 1, below:

Abstract: The present invention relates to ethynyl derivatives of formula I X, O, R1, R2, R3, R3?, R4, R4?, R5, R6, R6?, m, and n are as defined hereinor to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. Compounds of formula I are positive allosteric modulators (PAM) of the metabotropic glutamate receptor subtype 5 (mGluR5). They can be used for the treatment of schizophrenia or cognitive disorders.

Abstract: A compound for an organic optoelectronic device, an organic light emitting diode, and a display device, the compound including sequentially combined substituents represented by the following Chemical Formulae 1 to 3:

Abstract: The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection.

Abstract: A compound represented by Formula 1 or 2, and an organic light-emitting device including the same are disclosed. Formulae 1 and 2 are defined as in the specification.

Abstract: A condensed cyclic compound represented by Formula 1: wherein in Formula 1, Groups X1 to X3, L11, L12, R11, and R12, and variables a11, a12, b11, b12, c11, and c12 are described in the specification.

Abstract: A compound represented by Formula 1 or Formula 2 and an organic light-emitting device including the same:

Abstract: A pyrene-based compound is represented by Formula 1: where R11 to R14, L11, m11, n11, k11, a12, a13, and a14 are as defined in the specification.

Abstract: Provided are a compound of Formula 1 and an organic light-emitting device including the compound of Formula 1: The compounds of Formula 1 are particularly useful as fluorescent dopants in the emission layer of the organic light-emitting device.

Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide compounds which can be prepared from certain heteroaryl carboxylic acids and certain diazabicycloalkanes. The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the ?4?2 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle).

Abstract: The present description relates to compounds and forms and pharmaceutical compositions thereof and methods for use thereof to treat or ameliorate bacterial infections caused by wild-type and multi-drug resistant Gram-negative and Gram-positive pathogens.

Abstract: A condensed-cyclic compound represented by Formula 1 and an organic light-emitting device including the condensed-cyclic compound. wherein R1 to R10 are defined as in the specification.

Abstract: A compound for an organic photoelectric device, the compound being represented by the following Chemical Formula (“CF”) 1:

Abstract: A condensed cyclic compound and an organic light-emitting device including the same, the condensed cyclic compound being represented by Formula 1:

Abstract: Provided are a condensed compound and an organic light-emitting diode including the same, the condensed compound being represented by Formula 1 or 2:

Abstract: Provided is a compound represented by Formula 1, Formula 2, or Formula 3:

Abstract: The present invention is directed to compounds of Formula I: wherein X is N or CR1; Y is N or CR2; R1 is H, alkoxy, halo, triazolyl, pyrimidinyl, oxazolyl, isoxazole, oxadiazolyl, or pyrazolyl; R2 is H, alkyl, alkoxy, or halo; Z is NH or O; R3 is H, alkyl, alkoxy, halo, or triazolyl; R4 is H or alkyl; or R3 and R4, together with the atoms to which they are attached, form a 6-membered aryl ring or a 5- or 6-membered heteroaryl ring; R5 is pyridyl, pyrazinyl, or pyrimidinyl, wherein the pyridyl, pyrazinyl, or pyrimidinyl is optionally substituted with halo or alkyl; and n is 1 or 2. Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.

Abstract: A heterocyclic compound and an organic light-emitting diode including the same, the heterocyclic compound being represented by Formula 1, below:

Abstract: Provided is an organic electroluminescent device (organic EL device), which has improved luminous efficiency, has sufficient driving stability, and has a simple construction. The organic EL device of the present invention is an organic electroluminescent device, including a light-emitting layer and a hole-transporting layer between an anode and a cathode laminated on a substrate, in which the light-emitting layer contains a phosphorescent light-emitting dopant and an indolocarbazole compound that serves as a host material, or alternatively, the hole-transporting layer contains an indolocarbazole compound. The indolocarbazole compound is represented by the following formula (1). In the formula: A1's each represent an aromatic hydrocarbon group or an aromatic heterocyclic group, provided that at least one of A1's has a fused ring structure; and R1's each represent a hydrogen atom, an alkyl group, an alkoxy group, or an acyl group.

Abstract: An anthracene-based compound is represented by Formula 1 as below: wherein Ar, R1 to R3, R11 to R13, L1, L2, a1 to a3, b1, b2, n1, n2, m1, m2, o1 and o2 are as defined in the specification. An organic light-emitting device includes the anthracene-based compound.

Abstract: The present description relates to compounds and forms and pharmaceutical compositions thereof and methods for use thereof to treat or ameliorate bacterial infections caused by wild-type and multi-drug resistant Gram-negative and Gram-positive pathogens.

Abstract: A novel organic compound that can be used as a carrier-transport material, a host material, or a light-emitting material in a light-emitting element is provided. Specifically, an organic compound that can give a light-emitting element having favorable characteristics even when the organic compound is used in a light-emitting element emitting phosphorescence is provided. The organic compound has a bipyridine skeleton formed by two pyridine skeletons to each of which a dibenzothiophenyl group or a dibenzofuranyl group is bonded via an arylene group.

Abstract: A biscarbazole derivative of the invention is represented by a formula (1) below. In the formula (1): A1 represents a substituted or unsubstituted nitrogen-containing heterocyclic group having 1 to 30 ring carbon atoms; A2 represents a substituted or unsubstituted aromatic hydrocarbon group having 6 to 30 ring carbon atoms, or substituted or unsubstituted nitrogen-containing heterocyclic group having 1 to 30 ring carbon atoms; X1 and X2 each are a linking group; Y1 to Y4 each represent a substituent; p and q represent an integer of 1 to 4; and r and s represent an integer of 1 to 3.

Abstract: The present invention relates to a novel compound and an organic light emitting device using the compound, and the compound according to the present invention may largely improve a life span, efficiency, electrochemical stability and thermal stability of the organic light emitting device.